Study of characteristics and complications in young patients with myeloproliferative neoplasia
Children, Adolescents and Young Adults with Myeloproliferative Neoplasia: Study of Clinico-biological Characteristics and Complications
This study is trying to gather information about young people under 30 with myeloproliferative neoplasia to better understand their health and complications.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 0 Years to 30 Years |
| Sex | All |
| Sponsor | University Hospital, Brest Academic / other |
| Locations | 1 site (Brest) |
| Trial ID | NCT06715267 on ClinicalTrials.gov |
What this trial studies
This observational study aims to create a national database that captures the clinico-biological characteristics and complications of myeloproliferative neoplasia in patients under 30 years old. By collecting and analyzing data from these patients, the study seeks to provide a clearer understanding of their care and outcomes. Additionally, it will facilitate the identification of biological samples available in routine laboratories, allowing researchers to conduct further analyses to refine diagnoses and explore new molecular prognostic factors.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with non-LMC myeloproliferative neoplasia before the age of 30.
Not a fit: Patients who refuse to participate or are under legal protection may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding and management of myeloproliferative neoplasia in young patients, leading to improved treatment strategies.
How similar studies have performed: While this approach is focused on a specific age group and condition, similar observational studies have shown success in improving understanding of rare diseases.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient diagnosed with non-LMC MPN before the age of 30 (PV or TE or MFP or PreMF) according to the 2016 WHO criteria. * Signature of the consent form for participation in the FIMBANK project. * Agreement to participate in the VYP study. * Patient of legal age at the time of inclusion in VYP. * Patient affiliated to a social security scheme Exclusion Criteria: * Refusal to participate by patients of full age * Patient under legal protection (guardianship, curatorship, etc.)
Where this trial is running
Brest
- CHU de Brest — Brest, France (Recruiting)
Study contacts
- Study coordinator: Jean-Christophe IANOTTO
- Email: jean-christophe.ianotto@chu-brest.fr
- Phone: 0298223786
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.